Antibody targeting of TSG101 on influenza-infected cells

Virus Adaptation and Treatment

Volumn 2, Issue 1, 2010, Pages 147-157

  Bonavia, Aurelio ^a   Diaz, Leyla S ^a   Santos, David ^a   Cassella, Josephine ^a   Fesseha, Zena ^a   Bamba, Douty ^a   Sui, Baoquan ^a   Li, Wu Bo ^a   Duan, Roxanne ^a   Goldblatt, Michael ^a   Kinch, Michael S ^a   Chen, Li Mei ^b   Donis, Ruben O ^b  

^a Functional Genetics   (United States)

^b CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

Infected cells; Influenza; TSG101; Vaccine

Indexed keywords

MATRIX 1 PROTEIN; MATRIX PROTEIN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 4 8A4; TUMOR SUSCEPTIBILITY GENE 101 PROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTIGEN BINDING; ANTIVIRAL ACTIVITY; ARTICLE; BINDING AFFINITY; BINDING SITE; CELL SURFACE; CONTROLLED STUDY; DOG; DRUG SCREENING; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HOST CELL; INFLUENZA; INFLUENZA VIRUS; MORPHOGENESIS; NONHUMAN; PROGENY; PROTEIN DOMAIN; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; VIRION; VIRUS INHIBITION; VIRUS RELEASE;

EID: 79251474083     PISSN: None     EISSN: 11791624     Source Type: Journal    
DOI: 10.2147/VAAT.S13506     Document Type: Article

References (50)

1. Thompson WW, Shay DK, Weintraub E, et al. Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA. 2003;289(2):179-186.
2. Ong AK, Hayden FG. John F Enders lecture 2006: antivirals for influenza. J Infect Dis. 2007;196(2):181-190.
3. Nayak DP, Hui EKW, Barman S. Assembly and budding of influenza virus. Virus Res. 2004;106(2):147-165.
4. Schmitt AP, Lamb RA. Influenza virus assembly and budding at theviral budozone. Adv Virus Res. 2005;64:383-416.
5. Gomez-Puertas P, Albo C, Perez-Pastrana E, Vivo A, Portela A. Influenzavirus matrix protein is the major driving force in virus budding. J Virol. 2000;74(24):11538-11547.
6. Accola MA, Strack B, Gottlinger HG. Efficient particle production by minimal gag constructs which retain the carboxy-terminal domain of human immunodeficiency virus type 1 capsid-p2 and a late assembly domain. J Virol. 2000;74(12):5395-5402.
7. Latham T, Galarza JM. Formation of wild-type and chimeric influenza virus-like particles following simultaneous expression of only four structural proteins. J Virol. 2001;75(13):6154-6165.
8. Martin-Serrano J, Zang T, Bieniasz PD. HIV-I and Ebola virus encode small peptide motifs that recruit Tsg101 to sites of particle assembly to facilitate egress. Nat Med. 2001;7(12):1313-1319.
9. Garrus JE, von Schwedler UK, Pornillos OW, et al. Tsg101 and the vacuolar protein sorting pathway are essential for HIV-1 budding. Cell. 2001;107(1):55-65.
10. Pornillos O, Alam SL, Davis DR, Sundquist WI. Structure of the Tsg101 UEV domain in complex with the PTAP motif of the HIV-1 p6 protein. Nat Struct Biol. 2002;9(11):812-817.
11. VerPlank L, Bouamr F, LaGrassa TJ, et al. Tsg101, a homologue of ubiquitin-conjugating (E2) enzymes, binds the L domain in HIV type 1 Pr55(Gag). Proc Natl Acad Sci U S A. 2001;98(14):7724-7729.
12. Martin-Serrano J, Zang T, Bieniasz PD. HIV-1 and Ebola virus encode small peptide motifs that recruit Tsg101 to sites of particle assembly to facilitate egress. Nat Med. 2001;7(12):1313-1319.
13. Li L, Cohen SN. Tsg101: a novel tumor susceptibility gene isolated by controlled homozygous functional knockout of allelic loci in mammalian cells. Cell. 1996;85(3):319-329.
14. Slagsvold T, Pattni K, Malerod L, Stenmark H. Endosomal and non-endosomal functions of ESCRT proteins. Trends Cell Biol. 2006;16(6):317-326.
15. Perez OD, Nolan GP. Resistance is futile: assimilation of cellular machinery by HIV-1. Immunity. 2001;15(5):687-690.
16. Mazze FM, Degreve L. The role of viral and cellular proteins in the budding of human immunodeficiency virus. Acta Virol. 2006;50(2):75-85.
17. Myers EL, Allen JF. Tsg101, an inactive homologue of ubiquitin ligase e2, interacts specifically with human immunodeficiency virus type 2 gag polyprotein and results in increased levels of ubiquitinated gag. J Virol. 2002;76(22):11226-11235.
18. Panchal RG, Ruthel G, Kenny TA, et al. In vivo oligomerization and raft localization of Ebola virus protein VP40 during vesicular budding. Proc Natl Acad Sci U S A. 2003;100(26):15936-15941.
19. Freed EO. The HIV-TSG101 interface: recent advances in a budding field. Trends Microbiol. 2003;11(2):56-59.
20. Goila-Gaur R, Demirov DG, Orenstein JM, Ono A, Freed EO. Defects in human immunodeficiency virus budding and endosomal sorting induced by TSG101 overexpression. J Virol. 2003;77(11): 6507-6519.
21. Freed EO. Viral late domains. J Virol. 2002;76(10):4679-4687.
22. Chen BJ, Lamb RA. Mechanisms for enveloped virus budding: can some viruses do without an ESCRT? Virology. 2008;372(2):221-232.
23. Freed EO. Viral late domains. J Virol. 2002;76(10):4679-4687.
24. Clague MJ, Urbe S. Hrs function: viruses provide the clue. Trends Cell Biol. 2003;13(12):603-606.
25. Martin-Serrano J, Bieniasz PD. A bipartite late-budding domain in human immunodeficiency virus type 1. J Virol. 2003;77(22):12373-12377.
26. Masters PS. The molecular biology of coronaviruses. Adv Virus Res.2006;66:193-292.
27. de Haan CAM, Rottier PJM. Molecular interactions in the assembly of coronaviruses. Adv Virus Res. 2005;64:165-230.
28. Bouamr F, Melillo JA, Wang MQ, et al. PPPYVEPTAP motif is the late domain of human T-cell leukemia virus type 1 Gag and mediates its functional interaction with cellular proteins Nedd4 and Tsg101 [corrected]. J Virol. 2003;77(22):11882-11895.
29. Chiou CT, Hu CC, Chen PH, Liao CL, Lin YL, Wang JJ. Association of Japanese encephalitis virus NS3 protein with microtubules and tumour susceptibility gene 101 (TSG101) protein. J Gen Virol. 2003;84(Pt 10): 2795-2805.
30. Chua HH, Lee HH, Chang SS, et al. Role of the TSG101 gene in Epstein- Barr virus late gene transcription. J Virol. 2007;81(5):2459-2471.
31. Gottwein E, Bodem J, Muller B, Schmechel A, Zentgraf H, Krausslich HG. The Mason-Pfizer monkey virus PPPY and PSAP motifs both contribute to virus release. J Virol. 2003;77(17):9474-9485.
32. Hammarstedt M, Ahlqvist J, Jacobson S, Garoff H, Fogdell-Hahn A. Purification of infectious human herpesvirus 6 A virions and association of host cell proteins. Virol J. 2007;4:101.
33. Honeychurch KM, Yang G, Jordan R, Hruby DE. The vaccinia virus F13 L YPPL motif is required for efficient release of extracellular enveloped virus. J Virol. 2007;81(13):7310-7315.
34. Luttge BG, Shehu-Xhilaga M, Demirov DG, et al. Molecular characterization of feline immunodeficiency virus budding. J Virol. 2008;82(5):2106-2119.
35. Medina G, Pincetic A, Ehrlich LS, et al. Tsg101 can replace Nedd4 function in ASV Gag release but not membrane targeting. Virology. 2008;377(1):30-38.
36. Tanzi GO, Piefer AJ, Bates P. Equine infectious anemia virus utilizes host vesicular protein sorting machinery during particle release. J Virol. 2003;77(15):8440-8447.
37. Urata S, Noda T, Kawaoka Y, Morikawa S, Yokosawa H, Yasuda J. Interaction of Tsg101 with Marburg virus VP40 depends on the PPPY motif, but not the PT/SAP motif as in the case of Ebola virus, and Tsg101 plays a critical role in the budding of Marburg virus-like particles induced by VP40, NP, and GP. J Virol. 2007;81(9):4895-4899.
38. Urata S, Noda T, Kawaoka Y, Yokosawa H, Yasuda J. Cellular factors required for Lassa virus budding. J Virol. 2006;80(8):4191-4195.
39. Diaz L, Mao H, Zhou Y, et al. TSG101 exposure on the surface of HIV-1 infected cells: implications for monoclonal antibody therapy for HIV/AIDS. Am J Transl Res. 2010;2(4):368-380.
40. Hui EKW, Barman S, Yang TY, Nayak DP. Basic residues of thehelix six domain of influenza virus M1 involved in nuclear translocation of M1 can be replaced by PTAP and YPDL late assembly domain motifs (Retracted article. See vol. 80, p. 10289, 2006). J Virol. 2003;77(12):7078-7092.
41. Hui EKW, Barman S, Tang DHP, France B, Nayak DP. YRKL sequence of influenza virus M1 functions as the L domain motif and interacts with VPS28 and Cdc42 (Retraction of vol. 80, p. 2291, 2006). J Virol. 2006;80(20):10289.
42. Hillman MR. Realities and enigmas of human viral influenza: pathogenesis, epidemiology and control. Vaccine. 2002;20(25-26):3068-3087.
43. Scholtissek C, Quack G, Klenk HD, Webster RG. How to overcome resistance of influenza A viruses against adamantane derivatives. Antiviral Res. 1998;37(2):83-95.
44. Luscher-Mattli M. Influenza chemotherapy: a review of the present state of art and of new drugs in development. Arch Virol. 2000;145(11):2233-2248.
45. Gubareva LV, Webster RG, Hayden FG. Detection of influenza virus resistance to neuraminidase inhibitors by an enzyme inhibition assay. Antiviral Res. 2002;53(1):47-61.
46. Hayden F, Klimov A, Tashiro M, et al. Neuraminidase inhibitor susceptibility network position statement: antiviral resistance in influenza A/ H5N1 viruses (vol. 10, p. 873, 2005). Antivir Ther. 2006;11(1):130.
47. Reece PA. Neuraminidase inhibitor resistance in influenza viruses. J Med Virol. 2007;79(10):1577-1586.
48. Rameix-Welti MA, van der Werf S, Naffakh N. Sensitivity of H5N1 influenza viruses to oseltamivir: an update. Future Virol. 2008;3(2):157-165.
49. Lackenby A, Thompson CI, Democratis J. The potential impact of neuraminidase inhibitor resistant influenza. Curr Opin Infect Dis. 2008;21(6):626-638.
50. Singer AC, Howard BM, Johnson AC, et al. Meeting report: risk assessment of tamiflu use under pandemic conditions. Environ Health Perspect. 2008;116(11):1563-1567.